Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I-Reference-Cited by-同舟云学术

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Published:2021-06 Issue:6 Volume:32 Page:757-765
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Moore K.N.,Oza A.M.,Colombo N.,Oaknin A.,Scambia G.,Lorusso D.,Konecny G.E.,Banerjee S.,Murphy C.G.,Tanyi J.L.,Hirte H.,Konner J.A.,Lim P.C.,Prasad-Hayes M.,Monk B.J.,Pautier P.,Wang J.,Berkenblit A.,Vergote I.,Birrer M.J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference38 articles.

1. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances;Liu;Clin Cancer Res,2014

2. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N Engl J Med,2018

3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet,2017

4. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial;Ledermann;Lancet Oncol,2014

5. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N Engl J Med,2016

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature;Gynecologic Oncology Reports;2024-10

2. Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial;Gynecologic Oncology;2024-10

3. Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system;Scientific Reports;2024-09-13

4. Ocular side effects of anticancer agents used in the treatment of gynecologic cancers;Gynecologic Oncology;2024-09

5. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities;Gynecologic Oncology;2024-09